Erasca, Inc.

Listed Company

ERASCIK 0001761918NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-124.55M

Total Assets

$396.15M

Equity

$325.17M

Shares Out

310.80M

Op. Cash Flow

$-95.45M

Business

Erasca, Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for cancers driven by RAS/MAPK pathway alterations. It develops a modality-agnostic pipeline of targeted therapeutics and biologics, including its lead pan‑RAF inhibitor naporafenib and RAS‑targeting programs ERAS‑0015 and ERAS‑4001, plus antibody and kinase programs. Its programs align to three therapeutic strategies—targeting upstream/downstream MAPK nodes (MAPKlamp), direct RAS inhibition, and blocking treatment escape routes—and include internal development and external in‑licensing. Erasca advances programs through global clinical trials, strategic collaborations, licensing agreements, and plans for U.S. commercialization while pursuing partnerships for other territories.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	93	115	104	112	74
In-process research and development	10	23	—	102	—
General and administrative	39	42	38	33	23
Total operating expenses	141	180	142	247	125
Loss from operations	−141	−180	−142	−247	−125
Interest income	17	20	17	5	190,000
Other expense, net	−248,000	−2	−229,000	−257,000	—
Total other income (expense), net	16	18	16	5	2
Net loss	−125	−162	−125	−243	−123
Net loss per share, basic	−0.44	−0.69	−0.83	−1.99	−1.85
Net loss per share, diluted	−0.44	−0.69	−0.83	−1.99	−1.85
Weighted-average shares of common stock used in computing net loss per share, basic	284	234	150	122	66
Weighted-average shares of common stock used in computing net loss per share, diluted	284	234	150	122	66
Unrealized gain on marketable securities, net	223,000	328,000	1	−879,000	−164,000
Comprehensive loss	−124	−161	−124	−244	−123

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	74	68	93	284	360
Short-term marketable securities	202	231	219	151	54
Prepaid expenses and other current assets	10	10	8	9	6
Total current assets	286	309	321	444	420
Long-term marketable securities	66	142	10	—	45
Property and equipment, net	13	16	22	25	16
Operating lease assets	29	32	38	40	17
Restricted cash	408,000	408,000	408,000	408,000	408,000
Other assets	1	3	4	5	3
Total assets	396	503	395	515	501
Accounts payable	981,000	468,000	2	23	5
Accrued expenses and other current liabilities	22	26	20	24	21
Operating lease liabilities	5	5	4	1	285,000
Total current liabilities	29	31	26	49	26
Operating lease liabilities, net of current portion	42	47	52	54	19
Other liabilities	399,000	362,000	566,000	573,000	158,000
Total liabilities	71	79	79	103	45
Commitments and contingencies (Note 12)	—	—	—	—	—
Preferred stock, $0.0001 par value; 80,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024	0	0	0	—	—
Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2025 and 2024; 284,159,076 and 283,218,344 shares issued and outstanding at December 31, 2025 and 2024, respectively	28,000	28,000	15,000	15,000	12,000
Additional paid-in capital	1,217	1,191	923	894	695
Accumulated other comprehensive income	628,000	405,000	77,000	−1	−162,000
Accumulated deficit	−892	−768	−606	−481	−238
Total stockholders' equity	325	423	317	412	457
Total liabilities and stockholders' equity	396	503	395	515	501

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−125	−162	−125	−243	−123
Depreciation and amortization	3	4	4	3	829,000
Stock-based compensation expense	25	27	26	20	8
Accretion on marketable securities, net	−5	−10	−7	−994,000	108,000
Impairment charge on operating lease assets and property and equipment	—	5	—	—	—
Impairment charge on investment in equity securities	—	2	—	—	—
Prepaid expenses and other current and long-term assets	2	−2	939,000	−4	−7
Accounts payable	513,000	−2	−886,000	676,000	1
Accrued expenses and other current and long-term liabilities	−4	6	−2	5	12
Operating lease assets and liabilities, net	−2	−732,000	3	14	1
Net cash used in operating activities	−95	−109	−101	−103	−80
Purchases of marketable securities	−151	−403	−314	−132	−106
Maturities of marketable securities	261	269	245	80	60
In-process research and development	−10	−23	−20	−2	−8
Payment made for investment in equity securities	—	−157,000	—	−2	—
Purchases of property and equipment	−128,000	−60,000	−2	−15	−11
Net cash provided by (used in) investing activities	100	−157	−91	−71	−65
Proceeds from issuance of common stock in private placement, net of fees and expenses	—	44	—	—	—
Proceeds from the exercise of stock options	372,000	836,000	505,000	2	1
Proceeds from issuance of common stock under the Employee Stock Purchase Plan	724,000	800,000	790,000	820,000	1
Net cash provided by financing activities	1	241	1	98	439
Net increase (decrease) in cash, cash equivalents, and restricted cash	6	−25	−191	−76	295
Vesting of early exercised options	—	465,000	1	1	692,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro